MEDISPA.PRO
Ministry of Health code: A11.09.007 Axis M7 · Neuroplasticity and stress adaptation CEBM: Level D (Gas inhalation therapy)

Therapeutic inhaled xenon therapy

Therapeutic Xenon Gas Inhalation Therapy

Industry clinical and economic procedure passport. Full biological mechanism (MoA), patient preparation protocol, first-choice equipment fleet, integration into the resort's master treatment rooms and market price benchmarks.

To the procedure catalogue Equipment fleet Integration treatment rooms Rates and economics
Session duration
30 min
Turnover: ~45 min
Recommended course
10 sessions
every other day (4–6 procedures)
Throughput capacity
11 pts
per 8-hour shift
Median rate
42 050 ₽
36 025 ₽ – 48 075 ₽
Course cost
420 500 ₽
at market median
Publication volume
Level D
8 publ. in PubMed

Clinical profile

Inhalation of a xenon–oxygen mixture at subanaesthetic concentrations. Xenon is a well-studied anaesthetic with neuroprotective properties in experiments; for treating stress, anxiety and other wellness purposes there is only an open pilot study in panic disorder, with no randomised data.

Every statement links to a publication in the list below. This is a snapshot of published research, not a final assessment of the method: international practice and integrated protocols often run ahead of official publications. Draft based on published research; requires review by a physician. Revision: 2026-10-17.

Mechanism of action

  • In experiments, xenon protects organs during ischaemia and reperfusion, including at subanaesthetic concentrations. [5, 4]
  • In mouse models of Alzheimer's disease, xenon inhalation changed the state of microglia and reduced neuroinflammation and brain atrophy. [6]

Where studies show an effect

  • Panic disorder: an open uncontrolled study provided grounds for randomised trials. [1]
  • Neonatal seizures in asphyxia: subanaesthetic xenon with hypothermia stopped seizures for the duration of inhalation. [3]

Open questions and study limitations

  • In neonatal hypoxic-ischaemic encephalopathy, a single small pilot RCT is insufficient to draw conclusions about benefit and safety (Cochrane). [2]
  • Neuroprotection is confirmed mainly in animals; clinical benefit in stroke and brain injury awaits large trials. [4]
  • The high cost of xenon limits its use. [5]

Safety

  • In 12 studies, inhalation of a mixture with 28–47 % xenon was tolerated without sequelae by all but one person (marked dysaesthesia and brief loss of responsiveness). [7]
  • As an anaesthetic, xenon is notable for haemodynamic stability and favourable pharmacokinetics. [8]

Protocol in studies

  • In newborns, 30 % xenon was given for 24 hours alongside 72 hours of moderate hypothermia. [3]
Contraindications. Contraindications are determined by the anaesthesiologist according to the instructions for the gas mixture and device; they are not given in study abstracts.

Equipment fleet and fit-out

Certified first-choice medical equipment and compatible device systems

Equipment registry
Base configuration (Hero Device)
Tiamex-K / Kontur-Kh2 inhalation xenon anaesthesia and therapy device

Device platform with proven validation of the biological response. Includes built-in biofeedback sensor systems, patient protection protocols and precision dosing of exposure.

Certification: Russian Ministry of Health registration certificate / CE Medical Device Directive Class IIa/IIb.
Compatible platforms in the MEDISPA.PRO registry
NobiliXe therapeutic xenon system
Medical device, Roszdravnadzor registration certificate / CE
In the registry →

Architectural integration and treatment rooms

Resort rooms housing the treatment station (with SanPiN norms and MEP loads)

All treatment rooms →
1.3.6 18.0 m² · Class B

Xenon therapy room

General therapeutic interventions and high-tech therapy · Equipment: 2 643 400 ₽

Treatment room passport →

Unit economics and resort price benchmarks

Market analysis based on a sample of premium sanatoriums, wellness hotels and preventive medicine clinics

Market price corridor
25th percentile (P25) 36 025 ₽
Market median 42 050 ₽
75th percentile (P75) 48 075 ₽

Median of prices in industry facilities' price lists, 2026

Basis of the price benchmark

Prices for this procedure appear in the price lists of 2 industry facilities; the median and interquartile range across facilities are shown (each facility counts once).

Evidence base

For wellness and psychosomatic indications there is only an open pilot study and experimental data; there are no randomised clinical studies.

Publication level D · Scarce data
  1. 1.
    Xenon in the treatment of panic disorder: an open label study.
    J Transl Med, 2017 · Open-label study · PMID 28610592
    Panic disorder: the results justify double-blind RCTs of xenon.
  2. 2.
    Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy.
    Cochrane Database Syst Rev, 2018 · Cochrane systematic review · PMID 30123976
    A single small pilot RCT is insufficient to judge the benefit of xenon with cooling in newborns with encephalopathy.
  3. 3.
    Anticonvulsant effect of xenon on neonatal asphyxial seizures.
    Arch Dis Child Fetal Neonatal Ed, 2013 · Clinical study · PMID 23572341
    Subanaesthetic xenon stopped neonatal seizures; they returned after withdrawal.
  4. 4.
    Neuroprotective Properties of Xenon.
    Mol Neurobiol, 2020 · Review · PMID 31758401
    Neuroprotection by xenon in preclinical models; an RCT after cardiac arrest has been launched.
  5. 5.
    Xenon: recent developments and future perspectives.
    Minerva Anestesiol, 2009 · Review · PMID 18475253
    Organ protection in ischaemia models, including at subanaesthetic doses; the limitation is cost.
  6. 6.
    Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy.
    Sci Transl Med, 2025 · Experimental study · PMID 39813317
    In mice with Alzheimer's disease models, xenon inhalation reduced neuroinflammation and brain atrophy.
  7. 7.
    Side effects of xenon inhalation.
    J Comput Assist Tomogr, 1981 · Safety review · PMID 7264006
    Inhalation of 28–47 % xenon was well tolerated; one case of marked dysaesthesia is described.
  8. 8.
    Xenon: elemental anaesthesia in clinical practice.
    Br Med Bull, 2004 · Review · PMID 15728132
    Xenon as an anaesthetic: safety, haemodynamic stability, analgesia and neuroprotection.

Publications were found in PubMed; titles and journals are given verbatim, conclusions are a brief summary of the abstracts under the conditions of the specific studies. The level shows the volume of published data, not the value of the method: A — Plenty of data: consistent systematic reviews and meta-analyses of RCTs; B — Some data: reviews or several RCTs, results are heterogeneous; C — Little data: single RCTs or controlled studies; D — Scarce data: mainly reviews, observational and experimental studies. The passport is updated as new work is published and with regard to international practice.